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Treatment with a glycosaminoglycan formulation ameliorates experi-
mental diabetic nephropathy. Previous studies have indicated that admin-
istration of glycosaminoglycans can prevent some of the morphological
and physiological alterations which occur in experimental diabetic ne-
phropathy. The aims of this study were to further elucidate the effect of
these drugs on glomerular basement membrane permeability by dextran
clearance studies, to test the ability of glycosaminoglycans to revert
established diabetic nephropathy and to examine the effect of glycosami-
noglycans on renal extracellular matrix synthesis. Five groups of Sprague-
Dawley rats were studied for 12 months: two control groups (treated or
untreated non-diabetic), three streptozotocin diabetic animal groups, two
of which received a glycosaminoglycan formulation, one from the induc-
tion of diabetes and the other after the fifth month of diabetes. At five
months the 35S-sulfate glomerular incorporation, albuminuria, glomerular
basement membrane thickness and anionic charge density were deter-
mined. At 12 months albuminuria, renal collagen IV and perlecan mRNA
levels, anionic and neutral dextran clearances, glomerular basement
membrane morphometiy, and mesangial cell proliferation were evaluated.
We demonstrate that long-term administration of glycosaniinoglycans
prevents renal morphological and functional alterations in diabetic rats
and appears to revert established diabetic renal lesions. Glycosaminogly-
can administration modified renal matrix composition by the normaliza-
tion of collagen gene expression and increasing glomerular 35S-sulfate
incorporation.
We have previously reported that administration of glycosami-
noglycans (GAGs) chronically from the onset of diabetes pre-
vented glomerular basement membrane (GBM) thickening, gb-
merular anionic charge reduction, as well as the onset of
albuminuria in experimental diabetic nephropathy without affect-
ing glomerular filtration rate and metabolic control of the disease
[11. It has been shown that these drugs, irrespective of their
anticoagulant activity, are also capable of slowing down the
progression to uremia in rats with subtotal renal ablation [2, 31
and to ameliorate the nephropathy induced by chronic adminis-
tration of puromycin [41, or by habu snake venom [5]. The exact
mechanism of this "protective" effect of GAGs in experimental
diabetic and other models of nephropathy is not known, though
several hypotheses have been formulated: modulation of the
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coagulative cascade putatively involved in the pathogenesis of the
glomerulopathy [6], down-regulation of several proteases [41,
mechanical restoration of GBM anionic charges [2], and antimi-
togenic activity [5]. We have suggested as a plausible hypothesis
that GAGs affect matrix synthesis by glomerular cells [1]. This
study was designed: (1) to further elucidate the effect of these
drugs on GBM permeability by dextran clearance studies; (2) to
verify the ability of GAGs to revert established diabetic nephrop-
athy; and (3) to examine the ability of GAGs to effect renal matrix
synthesis by 35S-sulfate incorporation and steady-state mRNA
analysis for collagen IV and perlecan. These parameters were
chosen as: (1) 35S-sulfate incorporation effectively mirrors sul-
fated glycosaminoglycan synthesis due to the high incorporation
of free sulfate into glycosaminoglycans, and (b) collagen IV and
the heparan sulfate proteoglycan perlecan are the major compo-
nents of the GBM known to be consistently affected by experi-
mental nephropathy [7—10].
Methods
Treatment protocol
Diabetes was induced in 40 male Sprague-Dawley rats (Charles
River, Como, Italy) aged six to seven weeks (body wt ranging
between 225 and 250 g) by intravenous administration of 35 mg/kg
body wt streptozotocin (STZ) (Sigma Chemical Co., St. Louis,
Missouri, USA) in a citrate buffer (pH 4.5). Fifteen diabetic rats
served as diabetic controls (D), and starting immediately after
diabetes induction received 2 mI/kg/day of saline solution s.c. five
days weekly throughout the study. To another 15 rats with the
same time schedule, a chemically modified fast-moving heparin
(mH) (a-90-347, Alfa Wassermann SpA, Bologna, Italy) was
administered at 15 mg/kg body wt/day subcutaneously (preventive
protocol, D/mH/PP). The same drug was administered as above to
the remaining 10 animals starting from the fifth month (curative
protocol, D/mH/CP); until this time they received saline as the
control animals above. The chemical structure of this drug derives
from heparin, and is a glycosaminoglycan sulfate chain in which
the 2-0-sulfate iduronic acid is converted in the galacturonic acid
moiety. The molecular mass of mH is 10.4 kD, and the sulphate/
carboxylic ratio is 1.35; the compound has a very low anticoagu-
lant activity (110.2 j.Lg/ml is necessary to induce a doubling of the
aPTT time) [11]. The dosage was based on an equivalence for
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antithrombotic activity ED50 with the drugs used previously [11.
As non-diabetic controls, two healthy male animal groups were
utilized, one of which (C) consisted of 15 rats that received saline
solution as above. The other control group was 10 animals treated
with mH on the same schedule as the preventive protocol (C/mH).
Throughout the study, all rat groups were fed a standard diet
containing 20% protein (Altromin-R, Rieper, Bolzano, Italy).
Diabetes mellitus was successfully induced in all STZ treated rats.
No insulin treatment was given. During the 12 month follow-up,
one rat in the D/mH/PP, two rats in both the C and D/mH/CP
groups, and three rats in the D group died from infectious
diseases. No rats had hemorrhagic disorders. Before diabetes
induction, after five months, and at the end of the 12 month
follow-up, the rats were weighed and transferred to individual
metabolic cages for 24 hours for urine collection. Blood was
withdrawn only during the conclusive urine collection, 24 hours
after the last drug/saline administration. Creatinine was evaluated
by the creatininase method and glucose by glucose oxidase.
Albuminuria was assayed by the simple immunodiffusion tech-
nique using a rabbit anti-rat albumin antiserum and rat albumin as
standard (USB Immunochemicals, Cleveland, Ohio, USA).
Fifth month analyses
At the fifth month, four randomly selected animals in the C, D and
D/mH/PP groups were administered twice intraperitoneally with 1.0
mCi/100 g body wt of sodium 35SO4 (462 mCi/mMol, NEN, Du
Pont de Nemoirs, Dreieich, Germany). The injections (0.5 ml) were
given at 3.5 hour intervals according to Beavan et a! [12]. Three and
one-half hours after the second injection animals were anesthetized
with ketamine. Right kidneys were excised while the left kidney was
used for an in vivo perfusion with a solution containing 0.2%
ruthenium red (RR) (Carlo Erba, Milano, Italy) in Karnovsky's
aldehyde fixative at a flow rate of 4 to 5 mI/mm, with a perfusion
pressure ranging from 90 to 100 mm Hg for five minutes as
previously described [1]. The animals were then killed by exsangui-
nation with cardiac puncture following anesthesia. Small tissue
specimens were cut from the renal cortex of the upper pole of both
kidneys and fixed for 20 hours at room temperature in Karnovsky's
fixative (the right kidney) or in the same RR fixative mixture that had
been used for perfusion (the left kidney). After appropriate rinsing
and post-fixation, the specimens were dehydrated in ascending
ethanols and embedded in Epon 812. Thick sections from right
kidney cortices were cut and processed for autoradiography.
Twelfth month analyses
At the end of the follow-up, after 12 months from diabetes
induction, all rats except five randomly selected animals from each
group (C, C/mH, D, D/mHIPP, D/mH/CP) were sacrificed by
exsanguination following ketamine anesthesia. Their right kidneys
were excised, rapidly removed from the surrounding perirenal fat
and transversely sectioned. Cortex from the lower pole was
dissected and quick frozen in liquid nitrogen and stored at —80°C
for mRNA studies. The upper pole was formalin-fixed, paraffin-
embedded and sectioned for PCNA (proliferating cell nuclear
antigen) immunohistochemistry. Twenty-four to 30 hours after
the last s.c. drug/placebo administration, the five spared animals
per group were anesthetized with ketamine and placed on a
constant temperature table at 37°C. Heparinized polyethylene
tubing was inserted into the left femoral vein for infusion of inulin,
neutral and anionic dextrans, and in the abdominal aorta with the
tip at the left renal artery level for in vivo renal perfusion, and in
the left ureter for urine collection. Then, the right kidney was
excised and processed as above for mRNA studies and PCNA
immunohistochemistiy. A saline (0.9% NaCI) solution containing
10 Ci/ml '4C-inulin (NEN), 100 iCi/ml neutral 3H-dextrans
(NEN), and 10 tCI/ml anionic '251-dextrans was infused as a 0.6
ml bolus followed by a continuous intravenous infusion at a rate of
0.067 mI/mm. Blood samples (0.5 ml) were drawn from the
abdominal aorta at the beginning and end of the 30-minute urine
collection period and mixed in equal volumes in order to average
plasma concentrations of 3H-dextrans, 1251-dextrans, 14C-inulin.
Glomenilar filtration rate (GFR) and dextran clearances were
calculated by the standard formula. For the former, plasmatic and
urinary values were obtained by summing up 14C-inulin counts
from all the correspondent chromatographic samples (see below).
At the end of the clearance study, the left kidney was in vivo
perfused with 0.2% RR in Karnovsky's aldehyde fixative as
described above. The animals were then killed. Tissue specimens
from the renal cortex of the upper pole were fixed and embedded
in Epon 812 as described above for electron microscopy.
Autoradiography
Kidney sections were coated with Ilford KS emulsion (Ilford,
Mobberley, UK) at 43°C, and exposed for nine weeks in the
presence of silica gel, in the dark, at 4°C. At the end of the
exposure period the specimens were allowed to warm to 20°C and
then developed without agitation. Development was stopped after
three minutes using an acid step bath and the preparations were
fixed in Agefix (Agfa Gevaert, Leverkusen, Germany) for 15
minutes. After being washed in running tap water, they were
stained in 1% toluidine blue plus 1% borax solution for few
seconds. Micrographs were prepared using a Leitz light micro-
scope (Wetzlar, Germany).
Steady-state mRI'JA analysis
Total RNA was isolated from the frozen cortex by the method
of Chomczynski and Sacchi [13]. The frozen material was imme-
diately dispersed in the lysis buffer to limit the possibility of
degradation. RNA yields were determined spectrophotometri-
cally, and all samples used had a 260/280 nm ratio of 1.9 or
greater. Dot blots on nitrocellulose membranes of serial dilutions
of the RNA were made using a Schleicher and Schuell Minifold
apparatus as follows: 40 jg of total RNA were adjusted to 10%
formaldehyde in lOX sodium-sodium citrate (SSC) (20X SSC =
3 M NaCl, 0.3 M sodium citrate, pH 7.0). Serial dilutions (1:1) were
then made with an equal volume of the same buffer containing
tRNA as carrier, mixing, and removal of 1 volume for the
following dilution. The serial dilutions (20, 10, 5 and 2.5 .Lg), were
then vacuum blotted onto nitrocellulose (Schleicher and Schuell)
equilibrated in 20X SSC. The wells were rinsed with 20x SSC, the
blots removed and UV cross linked in a Stratalinker apparatus
(Stratagene, La Jolla, California, USA) while still wet. Clone 16
encodes a portion of murine perlecan [14] which was found to
cross-hybridize well with rat RNA. A Pst I fragment was isolated
from the plasmid p-CIV-1-c87 (supplied by Dr. Steven Ledbetter,
Upjohn Co., Kalamazoo, Michigan, USA) which contains the 5'
end of the al chain of collagen IV eDNA. As a control, a 0.6 kb
Pst 1-Eco RI fragment containing a portion of the sequence of
cyclophillin, a "housekeeping" gene, was used. These cDNA
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clones were radiolabeled by random priming (Boheringer Mann-
heim, Mannheim, Germany) and hybridized with the dot blots.
The hybridizations and washes were performed under stringent
conditions as previously described [15]. Blots were then exposed
to Kodak X-Omat AR X-ray film. For reprobing, blots were
stripped by incubating at 95°C in 0.02X SSC 0.2% SDS. Autora-
diograms were quantitated by scanning on an LKB Ultroscan
peak for each dot. The data from each dilution were then plotted
to observe the linear portions of each series. Only samples which
had a correlation coefficient greater than 0.95 in their linear range
(minimum of 3 data points) were used. As the 10 jg point fell
within the linear range for all samples, this point was used for all
calculations. Data were expressed in optical density units (OD).
Morphometric analysis
Morphometric analysis on electron microscopic images was
carried out blind on six glomeruli, for a total of 36 to 72 randomly
selected GBM areas (final magnification X40000) in each case. By
means of a semiautomatic procedure with an image analyzer (Ibas
2000 Kontron, Carl Zeiss, Yena, Germany), the GBM thickness
and the density of anionic charges stained by RR in the lamina
rara externa were determined. Values were expressed as the
number of RR precipitates per 1000 nm of GBM linear length.
The morphometry of autoradiographic specimens was carried on
with the same apparatus on 5 to 8 glomeruli per animal, 4 to 7
sections/glomerulus (final magnification X 1000) by mean of an
automatic segmentation procedure. Their number was deter-
mined based on the grey value of the silver grain precipitates.
PCNA study
Immediately adjacent sections obtained from paraffin-embed-
ded kidney specimens were evaluated blindly if they contained at
least 20 glomeruli each. They were processed with a murine
monoclonal antibody against human PCNA (Dako, Denmark)
(avidin-biotin immunoperoxidase) and, for identification of me-
sangial cells, with a murine monoclonal antibody raised against
muscle specific actin isoforms (HHF-35, Enzo Biochemicals, New
Jersey, USA) [16] (avidin-biotin-immunoperoxidase). The latter
antibody should be specific for proliferating mesangial cells, since
a-actin is expressed only by proliferating mesangial cells and not
quiescent mesangium as recently demonstrated [17]. For all
specimens the negative control consisted of substituting the
primary antibody with nonimmune murine serum. Proliferation
was expressed as the numbers of nuclei per glomerular cross
section that were positive for PCNA, The percentage of PCNA-
positive nuclei and HHF-35-positive cells was calculated for 20
adjacent glomeruli in each animal.
Preparation of radiolabeled dextrans
Tritium radiolabeling of neutral dextrans having an average mol
wt 40 kD (Sigma) was performed by NEN with tritium by
oxidation with periodate, followed by reduction with tritiated
sodium borohydrate according to Chang et a! [18]. This same
neutral dextran was sulfated to obtain an anionic compound using
the method of Woods and Mora [19]. Briefly, 40 ml anhydrous
pyridine were placed in a flask, and 10 ml of chlorosulfonic acid
were added drop wise with vigorous stirring keeping temperature
below 0°C. Thereafter, the reaction mixture was brought to 50°C,
and 5 g of neutral dextran added. The reaction mixture was
maintained at 60°C with stirring for five hours, and was then
neutralized with sodium hydroxide to pH 7.0. The dextran sulfate
was precipitated from the solution with ethanol, dialyzed against
deionized distilled water, and lyophilized. Chemical analysis of the
product indicated a sulfate molar ratio of 1.65 and no depolymer-
ization. '25lodine radiolabeling of the sulfated dextran was per-
formed according to Yoshioka et al [20]. Five hundred milligrams
of dextran sulfate were then dissolved in 12.5 ml of a 0.2 M Na104
solution and kept 24 hours in the dark at room temperature.
Thereafter, dextran oxidation was stopped with 1 ml ethylene
glycol. The oxidized dextran solution was dialyzed against re-
peated changes of distilled water and added to a solution contain-
ing 0. 2 M borate buffer (pH 9.0) and 0.1 M tyramine in 0.1 N HCI,
mixed, and kept at room temperature for two hours. The mixture
of oxidized dextrans was reduced with 1% NaBH4, and the excess
of NaBH4 was neutralized by the addition of acetone. After
dialysis, the dialysate was centrifuged at 8000 rpm for 40 minutes,
and the supernatant was then lyophilized. The dextran was then
purified by precipitating it in a solution of sodium acetate in
ethanol, filtering and washing in absolute ethanol, and finally
drying under vacuum at 40°C. This purified dextran was solubi-
lized in a phosphate buffer (pH 7.4) and labeled with 20 pJ 1251
(100 tCi) by incubation with 5 units IODO-Bead (Pierce, Rock-
ford, Illinois, USA) for 15 minutes at 4°C. After labeling, 125j.
dextran was separated from free 1251 by chromatography through
a Sephadex G-25 column (PD-b, Pharmacia, Uppsala, Sweden)
equilibrated with phosphate buffer (pH 7.4). '25!-dextran was
collected and total radioactivity was counted in a gamma counter
(Beckman Instruments, Irvine, California, USA). After filtration
(0.45 m pore size filter, Millipore, Bedford, Massachusetts,
USA) the solution of iodinated dextran (specific activity 17
Ci/mg) was stored at 4°C in sterile vials.
Chromatographic procedures
Plasma and urine samples were assayed for 14C-inulm, as de-
scribed below, to determine GFR and then separated on a molecular
sieve column for 3H-neutral dextrans and '251-anionic dextran con-
tent by high performance liquid chromatography (Beckman Model
344) using a 7.5 X 360 mm Spherogel TSK 2000 column (Beckman)
with a 7.5 x 75 mm Sepharose Guard precolumn (Beckman). PBS
was used to equilibrate the chromatographic system and to dilute the
samples (up to 500 jLl) before sieving at a flow rate of 1 ml/min; the
absorbance of the eluate was monitored at 214 nm. Fractions of 1 ml
were directly counted for 125! (anionic dextran) radioactivity in a
gamma counted (Beckman), and then dissolved in 5 ml of Ultima
Gold (Packard, Groningen, The Netherland) and counted for 3H
(neutral dextran) in a LS18O1 Beckman scintillation counter using
0-400 and 400-670 adjusted quenching windows. The column was
calibrated using bovine serum albumin and ribonuclease A (Phar-
macia).
Statistical analyses
One-way analysis of variance (ANOVA) was used for glomer-
ular filtration rate (creatinine clearance), dextran clearances,
albuminuria, type IV collagen mRNA and perlecan mRNA, and
two-way ANOVA for 5 and 12 month morphometric parameters,
and autoradiographic data. The latter analyses enabled evaluation
of the effect of both treatment and animal variability on charge
density, GBM thickness, and 35S-sulfate glomerular incorpora-
tion. After ANOVA, specific hypotheses regarding differences in
morphometric parameters among groups were tested by contrasts
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Table 1. Parameters evaluated at 5 and 12 months of follow-up in control (C) and diabetic (D) rats treated with a fast moving heparin with a
preventive protocol (C/mH, D/mH/PP), and in diabetic rats with a curative schedule (D/mH/CP)
Time
months C C/mH D D/mHIPP D/mH/CP
Body wt g 12 798 38 (9) 721 28(10) 385 21(8) 369 24(10) 390 27(8)
Glycemia mg/dl
GFR mi/mm/kg body wt
12
12
112,3 4.1 (9)
7.21 0.84 (9)
129.8 3.9 (10)
8.01 0.92 (10)
732.3 56.2 (8)
10.20 1.89 (8)
838.7 68.2 (10)
9.76 2.01 (10)
791.0 49.5 (8)
9,43 1.64 (8)
Albuminuria mg/24 hr 5
12
3.5 1.3 (15)
20.9 7.5 (9)
—
13.4 4.6 (10)
18.2 4.7 (13)
116.0 31.9 (8)
7.0 1.8 (15)
38.8 8.5 (10)
—
18.5 2.4 (8)
GMB thickness nm 5
12
263 6 (4)
460±12(4)
—.
420±21(4)
297 7 (4)
536±11(4) 420±12(4)
—
415±9(4)
GBM charge density 5 44.9 1.4(4) — 39.7 1.0(4) — —
points/1000 nm
35S incorporation
Ag grains/1000 2
12
5
42.4 1.2 (4)
62 4 (4) 52.3 1.7 (4)— 32.2 0.6 (4)20 5 (4) 45.2 1.3 (4)37 3 (4) 49.4 2.3 (4)—
Collagen IV mRNA (OD) 12 0.49 0.06 (5) 0.58 0.06 (7) 0.77 0.07 (5) 0.50 0.05 (7) 0.51 0.05 (5)
Perlecan mRNA (OD) 12 0.39 0.06 (5) 0.17 0.02 (7) 0.31 0.02 (5) 0,21 0.02 (7) 0,23 0.04 (5)
Data are mean SEM (number of rats).
(linear combinations of means). Bonferroni's test for multiple
comparisons was applied to GFR and albuminuria values. The
Kruskal-Wallis non-parametric test was employed to compare the
average percentages of PCNA- and HHF-35-positive cells.
Results
Mean values and standard errors of the parameters concerning
glycemia, body weight, creatinine clearance, GBM thickness,
GBM charge density, 35S-sulfate incorporation, albuminuria, type
IV collagen mRNA and perlecan mRNA are reported in Table 1.
Metabolic control, with reference to glycemia and body weight,
was similar in all diabetic groups. Albeit diabetic groups had a
trend towards higher GFR values with respect to healthy rats, the
differences were not significant (F 0.67, Table 1).
After five months, diabetic animals showed ultrastructural and
functional evidence of renal involvement; in fact albuminuria was
mildly increased (F 7.18; P < 0.002; Fig. 1), as well as GBM
thickness (F = 4.69; P < 0.02; Fig. 2), while GBM charge density
was decreased (F 4.02; P < 0.02; Fig. 3). After 12 months, the
urinary albumin excretion was markedly increased in untreated
diabetic rats (F = 8.61; P = 0.000). However, there was no
significant difference between control and either the C, C/mH,
D/mHIPP or D/mH/CP groups or between the D/mHIPP and
D/mH/CP groups for urinary albumin excretion (Table 1, Fig. 1).
There was no difference in neutral dextran fractional clearances
among the C, D, and DImHIPP groups over the entire range of
molecular radii studied (24 to 50 A); on the contrary, diabetic
animals had a higher anionic dextran clearances for radii greater
than 43 A (Fig. 4), but there was no significant difference between
the DImHIPP and the C group for radii over 45 A (Fig. 4).
At 12 months, GBM thickness was greater in the D group as
compared to healthy control animals, to the C/mH group, and to the
D/mHJPP and D/mH/CP groups (F = 18.55;P = 0.000). There were
no significant differences in GBM thickness between the control and
the CImH, and D/mH/PP, and the D/mHICP groups (Table 1, Fig.
2). The GBM charge density was significantly lower in D animals
(F = 20.79; P = 0.000) in respect to all other groups. C/mH group
had significantly higher charge density also in respect to the control
and the DImHIPP groups (P < 0.001 and P < 0.01, respectively;
Table 1, Fig. 3). The steady state level of perlecan mRNA in diabetic
--
C CImH 0 D/mH/PP D/mH/CP
B P<O.001 P<0.O1
Fig. 1. Albumin urinaiy excretion (mean and SEM) in control rats (C), in
diabetic rats (D), in healthy and diabetic rats treated with a fast moving
heparin with the preventive protocol (C/mH and D/mH/PP, respectively), and
in diabetic rats treated with the curative (D/mH/CP) schedule, at 5 (shaded
columns) and 12 months (F = 7.18; P = 0.002 and F = 8.61; P 0.000
respectively). A. Significancy bars refer to 12 month values, B are 5 month
data.
animals (D) was not statistically different from that of healthy
animals (C); however, it was reduced in all treated groups (C/mH,
D/mH/PP, D/mH/CP) (F = 8.58; P = 0.000) with respect to
untreated control animals (Table 1, Fig. 5; P < 0.001, < 0.005, <
0.005, respectively). Type IV collagen mRNA in diabetic rats (D) was
significantly increased with respect to all other groups (F = 5.01;P <
0.002), but there was no significant difference between those other
groups (Table 1, Fig. 6). Autoradiography disclosed a reduced
glonierular 35S-sulfate incorporation in the D group (F =28.4; P =
0.000) with respect to both C (P < 0.001) and DImH/PP (P < 0.02)
groups. The DImH!PP group also showed lower 35S-sulfate incorpo-
ration than in controls (P < 0.01) (Table 1, Fig. 7). No difference
emerged within groups for GBM thickness, GBM charge density and
35S-sulfate incorporation (F = 1.90, 0.98, 2.31, respectively).
A
Pe:0.001 P<0.001
P<0.001
P<o.001
P.<0.001
I
200
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Fig. 2. Glomerular basement membrane thickness (mean and SEM) in
control rats (C), in diabetic rats (D), in healthy and diabetic rats treated with
a fast moving heparin with the preventive protocol (C/mH and DImH/PP,
respectively), and in diabetic rats treated with the curative (DImH/CP)
schedule, at 5 (shaded columns) and 12 months (F = 4.69; P < 0.02 and F
= 18.55; P = 0.000 respectively). A. Significancy bars refer to 12 month
values, B are 5 month data.
Fig. 3. Anionic charge density (mean and SEM) in the glomerular basement
membrane in control rats (C), in diabetic rats (D), in healthy and diabetic rats
treated with a fast moving heparin with the preventive protocol (C/mH and
D/mH/PP, respectively), and in diabetic rats treated with the curative
(D/mH/CP) schedule, at 5 (shaded columns) and 12 months (F 4.02; P <
0.02 and F = 20.79; P < 0.001 respectively). A. Significancy bars refer to 12
month values, B are 5 month data.
801
A P<0.005 P<0.001
P<0.001 P<0.001
E
0)
0
-C
a
A
500
250
0
B PczO.02
C C/mH D D/mH/PP D/mH/CP
/
I • •
B
A P<0.005 P<0.001
P<0.001 P<0.001 P<0.005
P<0.01E
a
0)C
a)V
a)C)
0
a
75
50
25
0
10-i
0C
10-2
x
a)a
10_i
10-'
0C
10
10-2
C
a)a
10_i. -
20
Molecular radii, A
Fig. 4. Fractional clearances of neutral A and anionic B dextrans in control
(C, LI), in diabetic (D, •) and in heparin treated diabetic (D/mH/PP, .) rats
at 12 months. SEM was lower than 10% of mean values for all the evaluated
molecular radii. Statistically significant different anionic dextran clear-
ances between C and D/mH!PP vs. D animals are framed by the square.
logical and functional abnormalities in GBM induced by diabetes
[1]. In fact, administration of mH-glycosaminoglycans in diabetic
rats was capable of preventing GBM thickening (Fig. 2) and the
reduction in GBM anionic charges (Fig. 3), while maintaining
normal urinary albumin excretion (Fig. 1). Dextran clearance
analyses unequivocally demonstrate that glycosaminoglycans can
prevent alterations in GBM permeability, as suggested by their
ability to reduce albuminuria [1, present data]. In fact, the charge
C C/mH
B P<0.02
0 D/mH/PP D/mH/CP
I • I • I
30 40 50
Finally, on the average, less than 1 PCNA-positive cell and less
than 1 HHF-35-stainable cell per animal were observed in all
groups, without showing any significant differences (P 0.28 and
0.45, respectively).
Discussion
This study confirms previous observations that chronic admin-
istration of glycosaminoglycans is capable of preventing morpho-
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permselectivity in heparin-treated diabetic rats was similar to the
healthy control rats, whereas the untreated diabetic animal had
abnormally high clearances over 45 A (Fig. 4).
The dextran glomerular permeability data seem to mirror previous
observations in humans that GBM charge selectivity to macromole-
cules is compromised in early diabetic nephropathy and precedes a
size selectivity derangement [21—23]. It should be noted that the
correction of GBM permeability parallels the conservation of GBM
morphology, that is, normal GBM width and anionic charge density,
thus providing evidence that abnormal permselectivity is directly
related to these ultrastructural alterations.
Furthermore, here we show that it is possible to reverse
established GBM diabetic lesions, leading to a normalization of
GBM morphology and function. After five months the diabetic
animals had mild, albeit significant, signs of nephropathy which
were reversed following seven months of mH therapy. The ability
of GAGs to reverse GBM abnormalities is unique in that previous
studies have demonstrated that pancreatic islet transplantation
was not able to reverse changes in GBM thickness [24, 25]. This
paradox may be due to the prolonged half-life of some cellular
changes induced by diabetes [26—28]. It is possible that these
heparin species affect different points in the cellular metabolism
than diabetes, "forcing" a correction of matrix synthesis which
does not occur with the normalization of glycemia or insulinemia
alone. Certainly the ability of mH-glycosaminoglycans to modu-
late matrix/GBM synthesis does not exclusively depend on cellular
changes induced by diabetes, since heparin treatment modulated
GBM production in the healthy rats as well. In fact, mH in healthy
animals induced an increase of GBM charge density and a
reduction of perlecan mRNA steady-state levels (Figs. 3, 5).
The mechanism of GAG activity on diabetic nephropathy is not
clear. However, the anticoagulant properties, hemodynamic ef-
fects, down-regulation of several proteases, a putative activity on
non-enzymatic glycation, and mechanical restoration of glomeru-
lar charge by these compounds seem insufficient to explain the full
picture of the preventive effects of GAGs in the above experimen-
tal models [reviewed in 1]. Furthermore, the possibility of an
anorexant effect of heparin leading to a reduced protein intake
and consequently to a diminished glomerular hyperfiltration
seems unlikely. In fact, such an effect has never been described,
and heparin treated animals did not significantly differ in weight in
respect to their own controls.
The mH-glycosaminoglycan preparation results in material
which is largely desulfated. Heparin maintains its activity in
different experimental models of nephropathies irrespective of its
sulfation ratio [3, 4]. The results we observed here with mH-
heparin are vety similar to those previously obtained with mole-
cules with different sulfation, such as a low molecular weight
heparin and a dermatan sulfate [1], confirming that even great
variations in the sulfation ratio of the exogenous GAGs are not
critical for the ability of these molecules to prevent or reverse
nephropathic damage. Although an abnormal sulfate metabolism
has been described in diabetic animals [27], the large indepen-
dence of the activity from the degree of sulfation suggests that
mere supply of sulfate does not explain the GAG effect on
diabetic nephropathy.
The antiproliferative activity of GAGs or the possibility that
these compounds modulate matrix!GBM synthesis give more
likely explanations of their effects. The antimitogenic effect of
GAGs on a number of cells is well known [29—32]. GAGs have
also been shown to inhibit mesangial cell proliferation and
prevent disease progression in the subtotal nephrectomized rat
model [2, 3, 6, 33], in puromycin or habu snake-induced nephrosis
of the rat [4, 5], and in an experimental mesangioproliferative
glomerulonephritis [34]. The possibility that GAGs affect the
proliferation of mesangial and other glomerular cells in diabetic
nephropathy seems unlikely, since it is generally considered that
mesangial expansion in diabetes is due to the extracellular matrix
enlargement rather than to mesangial cell hyperplasia. Further-
more, we have demonstrated the lack of any glomerular prolifer-
ative wave in STZ diabetic rats 12 months after the induction of
diabetes [35], and our present results show no difference between
the treated and untreated diabetic and healthy groups concerning
PCNA and HHF-35 stainable glomerular cells.
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Fig. 5. Perlecan mRNA levels (mean and SEM) in the renal cortex at 12
months in control rats (C), in diabetic rats (D), in healthy and diabetic rats
treated with a fast moving hepann with the preventive protocol (C/mH and
D/mH/PP, respectively), and in diabetic rats treated with the curative
(D/mH/CP) schedule. F = 8.58; P = 0.000.
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Fig. 6. Type IV collagen mRNA (mean and SEM) levels at 12 months in
control rats (C), in diabetic rats (D), in healthy and diabetic rats treated with
a fast moving heparin with the preventive protocol (C/mH and DImH/PP,
respectively), and in diabetic rats treated with the curative (D/mH/CP)
schedule. F = 5.01; P < 0.002.
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Fig. 7. Autoradiographs showing 35S-sulfate in glomerular areas. Black points correspond to silver precipitates. Micrograph 1 is from a healthy rat,
micrograph 2 from a diabetic animal, and micrograph 3 from a group D/mH/PP rat.
GAGs have been demonstrated to modify the synthesis of
proteoglycans and of other matrix proteins in vascular smooth
muscle and endothelial cells, influencing the synthesis and com-
position of the extracellular matrix [36—38]. We have hypothe-
sized that these agents could have an effect on the synthesis of
matrix/GBM constituents by glomerular cells, leading to the
correction of some biochemical or cell functional abnormalities
responsible for GBM thickening and glomerulosclerosis [1]. The
results of the present study confirm the hypothesis that GAGs
affect matrix synthesis in vivo. Heparin treatment, in fact, altered
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type IV collagen (Fig. 6) and perlecan (Fig. 5) mRNA levels, and
increased glomerular 35S-sulfate incorporation (Fig. 7) in diabetic
animals.
Metabolic studies in experimental models have provided evi-
dence that enhanced production of collagen is a central event in
the development of diabetic glomerular extracellular matrix
abnormalities [39—41]. Increased immunohistochemical staining
to type IV collagen in the expanded mesangium and GBM in
diabetic nephropathy has been shown [42, 43], and in basement
membranes of human diabetic tissues increased levels of type IV
collagen have been observed [44]. In the KKAymouse and in the
WKY rat, two genetically transmitted models of NIDDM that
demonstrate thickening of the glomerular basement membrane
with duration of diabetes, as well as in the STZ-induced diabetic
rats, steady state levels of mRNA encoding type IV collagen
progressively increase [7—10], confirming our present results. The
observation that both type IV collagen mRNA and protein are
increased in the kidney of diabetic rats is consistent with increased
transcription of the corresponding gene in diabetes, rather than
with abnormal post-transcriptional processes or reduced collagen
degradation. The reduced type IV collagen mRNA levels in the
heparin treated diabetic animals probably reflect reduced collagen
synthesis as supported by recent findings obtained in experimental
mesangioproliferative glomerulonephritis where heparin inhibits
the overproduction of extracellular matrix proteins, including type
IV collagen [34]. However, in smooth muscle cells in culture,
heparin in the presence of the endothelial cell growth factor
appears to modulate the synthesis of collagen at a translational
and/or post-translational level, since the mRNA steady-state
concentrations were not significantly altered [36], and heparan
sulfate alone, whose chemical structure is strictly related to
heparin, increases type IV collagen synthesis in mesangial cells
[45]. It is evident that a more complex situation may be present in
vivo which leads to reduced collagen IV mRNA levels.
There was no difference in perlecan mRNA levels in D rats
(Fig. 5) similar to that observed in the non-insulin dependent
diabetes mouse model (KKAy) [7]. At first glance this is in
contrast with the reduced GBM anionic charge density, as these
charges correspond to heparan sulfate rich sites [46], and the
coexistent albuminuria which is believed to reflect an abnormally-
low GBM heparan sulfate content [47]. Some explanations of this
apparent contradiction can be rationalized. It has been observed
that the components of basement membrane interact in a highly
specific manner with a very strict stoichiometry, and that the
authentic architecture of the membrane (with consequent perme-
ability characteristics) can be achieved only as long as the
component precursors are secreted in correct concentrations [48,
49]. Thus abnormalities of the molar ratio between different
components of GBM, that is, perlecan and type IV collagen,
which are probable in light of our mRNA data, might have
profound consequences on the supramolecular organization of
GBM leading to the reduced anionic charge density observed in
diabetes. Alternatively, the decrease of GBM anionic charge
density in diabetic rats might be due to a reduced/abnormal
heparan sulfate expression with normal perlecan core protein
synthesis in the GBM as a consequence of post-transcriptional
processes (that is, impaired synthesis, enhanced degradation, or
reduced sulfation of the heparan sulfate carbohydrate chains).
The latter hypothesis is supported by the observation that the
normal perlecan mRNA levels in diabetic rats are in accordance
with normal staining with monoclonal antibodies against the
perlecan core protein in diabetic glomerulopathy, while the
staining with anti-heparan sulfate side chain antibodies is reduced
[50]. In addition, normal perlecan mRNA levels but reduced
levels of N-deacetylase, a critical enzyme involved in heparan
sulfate side chain sulfation, are found in short-term diabetes [51].
In both healthy and diabetic heparin-treated rats, a trend
towards reduced perlecan steady-state mRNA levels appears
which might be expression of a down-regulatory mechanism (Fig.
5). However, heparin also appears to have a regulatory activity at
the level of translational or post-translational processing of pro-
teoglycans. In mesangial cell cultures it increases heparan sulfate
synthesis and 35S-sulfate uptake [37, 52], and on endothelial cells
it increases the synthesis and sulfation of heparan sulfate [38].
Thus, the ameliorated anionic charge density in the GBM in
heparin treated animals (Fig. 3) may depend on the effect of these
agents on sulfation or synthesis of the heparan sulfate side chains.
The results of our 35S-sulfate autoradiographic study support this
concept (Fig. 7), in that while diabetic animals had a very low
silver grain density (corresponding to decreased 35S-sulfate incor-
poration) confirming previous observations [29], the heparin
treated animals had an increased grain density which most likely
reflects a stimulated sulfate/glycosaminoglycan metabolism. It is
clear that these changes are not due to alterations in perlecan
mRNA levels (reflecting core protein synthesis), as this is not
changed in the diabetic untreated animals and is lowered in
heparin treated animals. The increased 35S-sulfate incorporation
is more likely due to either increased side chain sulfation and/or
increased synthesis of other proteoglycan species.
In conclusion, our study demonstrates that the favorable effect
of glycosaminoglycans on GBM morphology and function in
experimental diabetes depends on their activity on the synthesis of
matrixlGBM molecules by glomerular resident cells.
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